Liminatus Pharma (LIMN) Stock: Buy, Sell, or Hold?
LIMN - Liminatus Pharma, Inc. Class A Common Stock
$3.47
-0.16 (-4.41%)
âŧ
5d:
-6.22%
30d:
+3098.16%
90d:
+2451.47%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 02, 2026
19d
Get Alerted When LIMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LIMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LIMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LIMN is currently trading at $3.47, which is considered slightly high relative to its 30-day fair value range of $0.23 to $4.20.
Technical Outlook: Technically, LIMN is in a downtrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: LIMN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LIMN is in a downtrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: LIMN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.23 -
$4.20
Company Quality Score
32/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
23.5%
All Signals
- BEARISH: Weak technical setup (0/100)
- BEARISH: Downward momentum (-4.4%)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.23 -
$4.20
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.74
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Share & Embed Analysis
Last updated: September 12, 2026 3:10 PM ET
Data refreshes hourly during market hours. Next update: 4:10 PM
Data refreshes hourly during market hours. Next update: 4:10 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LIMN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |